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Abstract
Spontaneous clearance of hepatitis C virus (HCV) has frequently been associated with the presence
of HCV-specific cellular immunity. However, there had been also reports in chimpanzees
demonstrating clearance of HCV-viremia in the absence of significant levels of detectable HCV-
specific cellular immune responses. We here report seven asymptomatic acute hepatitis C cases
with peak HCV-RNA levels between 300 and 100.000 copies/ml who all cleared HCV-RNA
spontaneously. Patients were identified by a systematic screening of 1176 consecutive new
incoming offenders in a German young offender institution. Four of the seven patients never
developed anti-HCV antibodies and had normal ALT levels throughout follow-up. Transient weak
HCV-specific CD4+ T cell responses were detectable in five individuals which did not differ in
strength and breadth from age- and sex-matched patients with chronic hepatitis C and long-term
recovered patients. In contrast, HCV-specific MHC-class-I-tetramer-positive cells were found in 3
of 4 HLA-A2-positive patients. Thus, these cases highlight that clearance of low levels of HCV
viremia is possible in the absence of a strong adaptive immune response which might explain the
low seroconversion rate after occupational exposure to HCV.
Background
Spontaneous clearance of acute infection with the hepati-
tis C virus (HCV) has been frequently associated with a
strong HCV-specific cellular immune response [1,2]. Both
HCV-specific CD4+ and HCV-specific CD8+ T cell
responses were found to be stronger and longer lasting in
chimpanzees and humans who cleared HCV as compared
to individuals who developed a chronic course of the
infection [3-13]. However, HCV-specific cellular immune
responses were not always detectable in chimpanzees who
cleared the virus spontaneously [14]. In addition, we and
others have previously reported clearance of HCV in the
absence of seroconversion to an anti-HCV antibody-posi-
tive status [15,16]. Subsequently, HCV-specific T cell
responses in HCV-exposed anti-HCV-negative individuals
have been demonstrated by several groups [17-20]
although it was not known in the latter studies whether
these subjects have transiently been viraemic for HCV or
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not. We had the chance to study prospectively individuals
with acute hepatitis C in the setting of a German young
offender institution. By systematic HCV-RNA screening of
1176 consecutive new incoming prisoners, we identified 7
HCV-RNA positive individuals who cleared HCV sponta-
neously during further follow-up. Four of those did never
develop anti-HCV-antibodies. HCV-specific T cell
responses could be monitored and were found to be
rather weak and not significantly different from chroni-
cally infected individuals. Thus, these cases highlight that
clearance of HCV-RNA may not necessarily correlate with
the appearance of acquired immunity, a finding that chal-
lenges our current understanding of the immunopatho-
genesis of HCV-infection.
Methods
Patients
Details of the study cohort were presented previously
[16,21]. In brief, all new incoming prisoners to the largest
German young offender institution for young men (age
16–24) were screened for anti-HCV antibodies and HCV-
RNA in the year 2002 (n = 1176). The study was approved
by the Ethics Committee of the Hannover Medical School
including additional blood sampling to study cellular
immune responses.
Subjects tested positive for any of the HCV-markers (n =
97; 8.6% of individuals screened) were offered to partici-
pate in a follow-up study on the course of HCV-RNA, ALT
levels and analysis of cellular immune responses. Follow-
up data and PBMC of seven patients who had cleared HCV
spontaneously were available for this study. In four of
them, intravenous drug abuse was the most likely source
of infection. Three patients reported unsafe sex before
imprisonment as the only risk factor possibly being asso-
ciated with HCV infection. Characteristics of the seven
subjects with cleared HCV-infection are shown in table 1.
Thirteen patients with chronic HCV infection (HCV-RNA-
positive at baseline and after 3 and 6 months of follow-
up) and 9 individuals with resolved HCV-infection (anti-
HCV-positive/HCV-RNA-negative at baseline and after 3
and 6 months of follow-up) identified in the same screen-
ing served as controls for the T cell assays. Characteristics
of control patients are shown in tables 2 and 3. Control
subjects did not differ in age (20.0 ± 1.4 years and 20.7 ±
1.4 years for patients with persistent infection and indi-
viduals being HCV-RNA-negative already at baseline) to
the seven study subjects (20.1 ± 0.8 years). All individuals
studied were male. None of the subjects had received anti-
viral therapy for HCV-infection prior to incarceration or
after imprisonment.
Serologic and virologic testing
Serum samples were tested for anti-HCV-antibodies using
a third generation HCV-ELISA (AxSYM-HCV Version 3.0,
Abbott Diagnostics, Wiesbaden, Germany). Antibody
reactivity against single HCV antigens was evaluated using
the immunoblot assay INNO-LIA HCV III Update (Inno-
genetics, Ghent, Belgium). HCV-RNA testing was per-
formed by Real-Time PCR (sensitivity 102 copies/ml) as
previously described [16,21]. For low viremic samples, we
always performed a second RNA extraction and applied a
second PCR with an alternative primer set and thus posi-
tive results in this study were based on at least two inde-
pendent extractions and two independent PCRs. The
HCV-RNA PCR has been validated and is used as a routine
Table 1: Characteristics of Cases with spontaneous HCV clearance
Subject # Age 
(Years)
Risk factor Duration 
of IVDU 
(months)
HLA class I Peak ALT 
(U/L)
HCV 
Geno-type
Peak HCV 
viremia 
(IU/ml)
Anti-HCV-
antibodies 
ELISA
Immuno- 
Blot 
(Inno-Lia)
1 19 Unsafe sex n.a. A03,11;B07,50
; Cw06,07
17 1 1 × 103 Negative Negative
5 20 Unsafe sex n.a. A01; B08; 
Cw07
21 1a 1 × 104 Negative Negative
10 19 IVDU 18 A02;B15,39; 
Cw03,07
81 b 3  ×  1 0 2 Positive Positive 
(6 proteins)
13 21 Unsafe sex n.a. A02,24;B07,44
; Cw04,07
22 1 7 × 103 Negative Negative 
faint band*
27 21 IVDU 72 A01,03;B35,57
; Cw04,06
12 1a 1 × 104 Positive Positive 
(4 proteins)
36 20 IVDU 10 A02,24;B42,35
; Cw04,17
25 1 5 × 104 Negative Negative
80 21 IVDU 24 A02,68;B14,44
; Cw07,08
250 1** Pos. Positive Positive 
(4 proteins)
(*) Patient 13 had a faint band against the C2 protein at the second time point investigated (after HCV clearance).
(**) Patient 80 had HCV serotype 1. Genotyping was not performed in the initial viremic sample and thus the HCV serotype was determined from 
HCV-RNA-negative follow-up samples.
n.a.: not applicableVirology Journal 2007, 4:58 http://www.virologyj.com/content/4/1/58
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diagnostic method in laboratory of the NLGA (Nieder-
sächsisches Landesgesundheitsamt) which is the central
laboraty of public health department of the state of Lower
Saxony. The frequency of HCV-RNA positive results in
anti-HCV-negative samples was always far below 1%.
T cell assays (Hannover Lab)
HCV-specific CD4+ T cell responses were investigated by
interferon-gamma ELISPOT-assays and proliferation
assays as described [22,23]. Antigens (HCV-core, HCV-
NS3, HCV-helicase, HCV-NS4, HCV-NS5a, tetanus tox-
oid) were purchased from Mikrogen (Munich, Germany).
Cyropreserved PBMC were used in all experiments. To
avoid inter-assay variability, all serial samples follow-up
of one individual were tested in the same assay. A stimu-
lation index (SI) of >2.5 in the proliferation assay was
considered positive (the mean SI in healthy controls + 3
standard deviations was <2.5 for all proteins tested). In
the ELISPOT-assay, a positive result was considered if
spot-forming units in the presence of antigen were at least
double of spot forming units in the medium control and
if at least five spots were detected per well.
Since patients recruited at the young offender institution
in Hameln had a high risk of potentially being exposed to
HCV due to previous drug consumption and HCV-specific
T cell responses have frequently been shown in seronega-
tive HCV-exposed individuals (including our own experi-
ence showing induction of HCV-specific T cell responses
after needle stick injury), we did not choose individuals
from the young offender institution as a "negative" con-
trol group but applied identical methods as for the other
projects run in the laboratory. T cell responses were inves-
tigated in the laboratory in several different cohorts of per-
sistently apparently unexposed HCV-RNA-negative
individuals showing frequencies of responses for the dif-
ferent assays of <5% for CD4+ T cell responses [23-25].
Positive controls were run in each assay. We had control
samples from patients with symptomatic acute hepatitis C
recruited in the Hep-Net acute HCV-II study [26] with a
robust HCV-specific CD4+ and CD8+ T cell response. Our
data on T cell responses of patients treated in the Hep-Net
acute HCV-II study have been described elsewhere [25].
Table 3: Characteristics of control patients who were anti-HCV+/HCV-RNA negative at incarceration and during follow-up of 6 
months.
Subject # Age (Years) Risk factor Duration of IVDU (months) Peak ALT (U/L) Anti-HCV-antibodies ELISA HCV-RNA
15 22 Unsafe sex n.a. 19 Positive Negative
30 22 n.a. n.a. 11 Positive Negative
35 20 IVDU 24 29 Positive Negative
40 20 n.a. n.a. 11 Positive Negative
50 21 IVDU 24 10 Positive Negative
59 20 n.a. n.a.- 6 Positive Negative
60 19 IVDU 10 55 Positive Negative
71 21 IVDU 2 16 Positive Negative
94 21 IVDU 24 321 Positive Negative
Table 2: Characteristics of control patients with chronic hepatitis C
Subject # Age (Years) Risk factor Duration of 
IVDU (months)
Peak ALT 
(U/L)
Peak HCV 
viremia (IU/ml)
Anti-HCV-antibodies ELISA Genotype
4 18 IVDU 6 168 1 × 106 Positive 3
12 18 IVDU 27 34 2 × 105 Positive 2
14 19 IVDU 18 44 2 × 106 Positive 1
29 20 IVDU 36 21 2 × 106 Positive 1
31 18 IVDU 72 715 9 × 106 Positive 1
32 20 IVDU 24 57 3 × 106 Positive 3
44 21 IVDU 84 49 4 × 105 Positive 2
48 22 Unsafe Sex n.a. 13 4 × 105 Positive 1
56 22 IVDU 60 193 1 × 106 Positive 1
57 22 IVDU 36 34 2 × 106 Positive 1
69 21 IVDU 36 94 1 × 104 Positive 3Virology Journal 2007, 4:58 http://www.virologyj.com/content/4/1/58
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HCV-specific CD8+ T cell responses were tested only in
HLA-A2-positive subjects since MHC-class I-HCV-tetram-
ers were available only for HLA-A2-restricted epitopes
(Table 4). HCV-tetramers were purchased from ProIm-
mune (Oxford, UK). PBMC (4 × 106  cells/ml) were
washed once with 0,1% BSA 0,1% sodium acide in PBS
and incubated seperately with four HLA-A2 restricted,
HCV-specifiv tetramers (all HLA*0201; Core-132 DLM-
GYIPAV; NS3-1073 CINGVCWTV; NS3-1406 KLVALGI-
NAV; NS5 ALYDVVTKL) for 20 min at 37°C. 1 μl of
antibodies (anti-CD8 APC, anti-CD27 FITC, anti-CD28-
FITC, anti-CD69 Cy, anti-CD45 RO FITC/PE (Beckdon
Dickinson, Heidelberg, Germany) were added for 10 min
at RT. After two washing steps, cells were analysed by flow
cytometry (FACS Calibur, Beckdon Dickinson, Heidelbeg,
Germany). 1 × 105 cells in the lymphogate were collected
for each analysis. Data were aquired with CELLQUEST
program (Beckdon Dickinson, Heidelbeg, Germany). In
addition, interferon-gamma ELISPOT-responses to a
panel of 8 selected peptides were tested as described [23].
ELISPOT assays (Vienna Lab)
Cryopreserved PBMC were also shipped to a second lab in
Vienna headed by CK. GCP-validated ELISPOT assays are
performed in this laboratory on a routine bases for meas-
uring T cell responses in clinical vaccine trials [27]. Assays
were performed exactly as previously described [28]. Since
not enough PBMC were available to screen for T cell
responses with overlapping peptides, a panel of synthetic
peptides representing ~30 MHC class I and class II T cell
epitopes derived from conserved regions of HCV was used
(Table 5). These peptides were identified in a systematic
screening with >400 overlapping peptides in PBMC from
65 HCV-recovered individuals (Klade et al., manuscript in
preparation). The 30 selected peptides have a cumulative
HLA coverage > 85%.
Results
Cases
Out of 97 subjects identified to be anti-HCV-positive and/
or HCV-RNA-positive during the initial screening after
incarceration, 90 individuals agreed to participate in the
follow-up study and were studied after 3 and 6 months for
HCV-RNA and ALT levels. At baseline 71 were HCV-RNA-
positive and 19 HCV-RNA-negative [16]. Seven of the
HCV-RNA-positive patients cleared HCV-RNA spontane-
ously after 8–31 weeks of follow-up. Characteristics of
these seven patients are shown in table 1 and the time
course of HCV viremia, ALT levels and T cell responses is
shown in figure 1. Only one subject (#80) had biochemi-
cal evidence of hepatitis with ALT levels higher than two
times upper the limit of normal. None of the individuals
reported significant symptoms associated with hepatitis
or developed jaundice. Liver function as determined by
albumin levels and prothrombine time remained normal
in all subjects at any time. Bilirubin levels were minimally
elevated once in patient #1 (1.23 mg/dl; normal value 1.1
mg/dl), and at three time points in patient #5 with levels
between 1.5 and 2.3 mg/dl. Mean peak HCV-RNA levels
were lower in the seven cases with spontaneous HCV
clearance than in 62 HCV viraemic patients who did not
Table 5: Sequences of peptides used for the ELISPOT-screen in the Vienna laboratory at Intercell AG.
HCV HLA coverage
ID antigen amino acid sequence class I class II
1798 NS4 IGLGKVLVDILAGYGAGVAGALVAFK A2, 3, 11 DR1, 4, 7
1799 NS3 AAWYELTPAETTVRLR B7/B35 DR1, 4
1624 E2 LEDRDRSELSPLLLSTTEW B*4001 DR7
1547 NS3 YLVAYQATVCARAQAPPPSWD A2 DR1, 4, 7, 11
1827 NS3 TAYSQQTRGLLG A24, B8? DR1, 7, 11
1829 NS5 SMSYTWTGALITP A2, B7, A24? DR1, 7, 11?
1846 E2 DYPYRLWHYPCTVNFTIFKV Cw7, A2, A11? DR1, 4, 7, 11
1754 E2 DYPYRLWHY Cw7
1835 Core KFPGGGQIVGGVYLLPRRGPRLGVRATRK A2, A3, B7 DR11
1855 NS5 SAKSKFGYG B8?
1843 Core LPRRGPRL B7
1844 Core GPRLGVRAT B7
1818 NS3 TPAETTVRL B7/B35
1838 NS4 SPGALVVGVI B7
1557 NS5 SSMPPLEGEPGDPDL B*4402?
Table 4: Sequences of HLA-A2-restricted peptides used in 
ELISPOT assays
Region Sequence Tetramer?
Core-35 YLLPRRGPRL No
Core-132 DLMGYIPLV Yes
Core-178 LLALLSCLTV No
NS3-1169 LLCPAGHAV No
NS3-1073 CVNGVCWTV Yes
NS3-1406 KLVALGINAV Yes
NS5-2594 ALYDVVTKL YesVirology Journal 2007, 4:58 http://www.virologyj.com/content/4/1/58
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recover from HCV (1.1 × 104 ± 1.6 × 104 copies/ml vs. 2.0
× 106 ± 3.8 × 106 copies/ml for patients with HCV clear-
ance and patients with persistent infection, respectively).
None of the seven patients was co-infected with HIV or
HBV.
Humoral Immunity
Anti-HCV antibodies as determined by a standard 3rd gen-
eration ELISA-assay remained negative throughout fol-
low-up in 4 of the 7 seven cases (Table 1). We also
investigated reactivity against single HCV proteins by the
INNO-LIA HCV III assay. A faint band against the C2 pro-
tein was found once in one of the four anti-HCV negative
patients while all anti-HCV-positive patients tested posi-
tive for at least four HCV-antigens at all time points (Table
1).
HCV-specific CD4+ T cell responses
Weak transient HCV-specific CD4+ T cell responses were
detected against at least one HCV protein either in the
interferon-gamma ELISPOT assay or in the proliferation
assay in five of the seven patients (figures 1 and 2). None
of the 4 patients who remained negative in the anti-HCV
ELISA (#1, #5, #13, and #36) had a CD4+ response that
was detectable at more than one time-point (figure 1).
Moreover, in all but one case (patient #36, first timepoint
investigated) only one protein tested positive in the anti-
HCV-negative patients.
Anti-HCV antibodies were already present at baseline in
patients #10 and #27 (figure 2). No HCV-specific CD4+ T
cell responses were found before or after HCV clearance in
these two patients. Subject #80 was the only individual
with biochemical evidence of hepatitis with about ten
times elevated ALT levels. A robust response against HCV-
helicase was found in the proliferation assay at baseline
and after clearance of HCV-RNA (SI values of 4.1 and 3.6,
respectively). At the second time point, we found also a
significant response against NS4 in the proliferation assay
as well as a helicase-specific interferon gamma response in
the ELISPOT assay detectable (figure 2).
Overall samples from 19 time points were investigated in
the 7 patients with spontaneous HCV clearance (2–4 time
points per patient as shown in figure 1). At least one HCV
protein was reactive in 4 (22%) of the ELISPOT-assays and
3 (16%) of the proliferation assays (table 6). In 7 cases
(37%) any of the two CD4 assays yielded at least one pos-
itive result. Comparing these results with ELISPOT assays
from control subjects from the same cohort with chronic
hepatitis C did not show any significant differences in fre-
quency, breadth and strength of CD4+ T cell responses.
Interferon gamma-ELISPOT responses were found in 6/24
assays (25%) performed in 13 subjects with chronic HCV
viremia. The mean number proteins recognized per assay
did also not differ between the two groups (table 6). Five
of the 13 chronically infected patients (38%) mounted at
least one positive interferon gamma response. The abso-
lute number of spot forming units in the ELISPOT-assay
in positive cases was not different in patients who had
cleared HCV and in chronic hepatitis C patients (mean
SFU 16.8 ± 1.1/106 PBMC for patients with clearance and
19.4 ± 4.8/106 PBMC for chronic HCV patients). HCV
long-term-recovered control patients (anti-HCV positive
and HCV-RNA-negative already at baseline) showed ELIS-
POT responses in 5/12 assays and proliferative responses
in 3/9 assays performed with samples from 9 individuals
also with a similar strength in responses (table 6).
HCV-specific CD8+ T cell responses
HCV-specific CD8+ T cell responses were investigated by
MHC-class I tetramer stainings in the HLA-A2-positive
patients. Patient #13 (anti-HCV-negative) displayed sig-
nificant responses for three HCV tetramers with frequen-
cies between 0.08% and 0.13% of CD8+ T cells at the
second time point (more than 6 months after HCV clear-
ance). The patient tested negative with the tetramer assay
at the two other time points (both after HCV clearance).
He also showed interferon gamma responses in the ELIS-
POT assay against five individual HCV peptides at the first
time point but not thereafter during follow-up. Patient #
36 (anti-HCV-negative) was negative in both assays
applied to investigate CD8+ T cell responses at both time
points when PBMC were available.
Patient # 10 (anti-HCV-positive) had the highest fre-
quency of HCV-tetramer-positive cells at baseline with
0.31% Core-132-specific, 0.99% NS3-1073-specific,
0.40% NS3-1406-specific and 0.4% NS5-specific
tetramer-positive CD8+ T cells. The frequencies of periph-
eral HCV-specific CD8+ T cells significantly declined as
compared with the second time point when PBMC were
available 3 months later. At this time, only HCV-NS3-
1073-specific T cells remained detectable with 0.11% of
CD8+ T cells. Patient #80 (the only patient with biochem-
ical evidence of hepatitis) had robust frequencies of NS3-
1073-specific T cells with 0.22% of CD8+ T cells at both
time points investigated. The other tetramers gave only
borderline responses with 0.05%-0.10% of CD8+ cells.
After clearance of HCV, interferon-gamma ELISPOT
responses were found against 4 peptides including the
NS3-1073 and core-132 in this subject.
IFN-gamma responses against 30 class I and II epitopes 
(Vienna lab)
Since only a limited number of PBMC was available
according to the study protocol approved the institutional
ethics committee, it was not possible to apply a full breath
screening for T cell responses with overlapping peptides.
Thus, we used a panel of 30 synthetic peptides represent-Virology Journal 2007, 4:58 http://www.virologyj.com/content/4/1/58
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Biochemical, virological and immunological course of acute hepatitis C in asymptomatic patients with spontaneous clearance:  patients with spontaneous clearance in the absence of anti-HCV Figure 1
Biochemical, virological and immunological course of acute hepatitis C in asymptomatic patients with spontaneous clearance: 
patients with spontaneous clearance in the absence of anti-HCV. HCV-RNA levels, ALT levels and T cell responses are shown. 
Coloured bars show the sum of SI values of the proliferation assay and the sum of specific interferon-gamma spots (spots in the 
presence of antigen – spots in the medium control) against 5 individual HCV proteins (HCV-core, HCV-NS3, HCV-helicase, 
HCV-NS4, HCV-NS5a). In addition, the number of individual proteins tested positive at the respective time point is shown for 
each assay. Interferon gamma ELISPOT responses were also tested against a panel of synthetic peptides representing class I and 
class II T cell epitopes derived from conserved regions of HCV with a cumulative HLA coverage > 85%. These assays were per-
formed in an independent second laboratory ("Pep-Screen ELISPOT"; Vienna lab). The number of peptides tested positive in 
this assay is also given.Virology Journal 2007, 4:58 http://www.virologyj.com/content/4/1/58
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ing ~30 class I and class II T cell epitopes derived from
conserved regions of HCV with a cumulative HLA cover-
age > 85%. These peptides were tested in an independent
second laboratory. Also in this T cell readout most
patients tested negative at all time points investigated.
Patient #1 tested positive for one HCV-class II peptide at
the first time-point investigated and was negative for all
peptides on subsequent time points. Patients #5, #10,
#13, #27, and #80 tested negative for all peptides at all
time-points investigated. Only subject #36 mounted a
robust multispecific response against at least 5 peptides
after clearance of HCV (figure 3) which were not HLA-A2-
restricted and thus no tetramer assays could be performed
in this study for this individual.
Biochemical, virological and immunological course of acute hepatitis C in asymptomatic patients with spontaneous clearance:  patients who developed anti-HCV antibodies Figure 2
Biochemical, virological and immunological course of acute hepatitis C in asymptomatic patients with spontaneous clearance: 
patients who developed anti-HCV antibodies.Virology Journal 2007, 4:58 http://www.virologyj.com/content/4/1/58
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Discussion
We here report seven cases of spontaneous clearance of
hepatitis C virus identified through a systematic screening
of young male subjects with a high proportion of iv-drug
addicts. We believe that the cases are of special interest for
several reasons:
(i) Four individuals never developed anti-HCV antibodies
in a standard 3rd generation ELISA-assay and also tested
negative in an anti-HCV immunoblot assay. Thus, with-
out screening for HCV-RNA these subjects would never
have been recognized as being infected with HCV. Similar
cases of HCV clearance in the absence of anti-HCV seron-
conversion have recently been described in four Austral-
ian IV-drug addicts [15]. In line with reports on HCV-
specific T cell responses in seronegative HCV-exposed per-
sons [17-20], it is very likely that the true rate of individu-
als in the general population who had contact with HCV
is underestimated, in particular in high risk persons such
as iv-drug addicts and maybe also in medical health pro-
fessionals. Our systematic unbiased screening approach of
all new incoming prisoners in a young offender institu-
tion [16] supports the conclusion that the percentage of
patients who are able to clear HCV viremia without devel-
oping anti-HCV antibodies might be much higher than
previously thought since the anti-HCV ELISA became pos-
itive in only three out seven patients.
(ii) HCV was cleared spontaneously even though the sub-
jects were asymptomatic and six out of seven had no bio-
chemical evidence of hepatitis. On the first view, these
findings somewhat contradict with several previous
reports suggesting that the likelihood to clear HCV spon-
taneously is the higher the more symptomatic a patient is
and the higher liver transaminases are [29,30]. We have
no information how many patients with similar character-
istics of exposure have developed chronic infection in our
setting since the subjects were identified in a cross-sec-
tional screening approach. At least 65 initially HCV-RNA
positive patients had persistent infection although we do
not know when these subjects had been infected before
incarceration [16]. Moreover, characteristics of our
patients differ from most other studies on acute hepatitis
C. Our patients were rather young with an age between 16
and 24 and the mode of infection was iv drug abuse in
almost all cases. Peak HCV-viral load with levels between
3 × 102 and 5 × 104 copies/ml was 2–3 logs lower than in
patient cohorts on acute hepatitis C that were enrolled in
treatment trials [26,31,32]. Nevertheless, for the manage-
ment of acute hepatitis C patients our study supports the
concept to investigate the kinetic of HCV-viremia for 2–3
weeks before an antivirial therapy is considered [33] – at
least for individuals with a viremia of < 5 × 105 IU/ml. If
Table 6: Summary of HCV-specific T cell responses obtained with different assays in the three different groups of patients studied
Proliferation Assay Class II ELISPOT assay Class I Tetramer Assay
Number 
of patients
Time points 
with at least 1 
positive protein
proteins tested 
positive/time point 
(mean number)
Time points 
with at least 1 
positive protein
proteins tested 
positive/time point 
(mean number)
Time points with 
at least 1 positive 
tetramer
tetramers 
tested positive/
time point (n)
Index patients 
(Acute 
resolving 
hepatitis C)
7 3/19 (16%) 0.26 4/19 (22%) 0.42 5/9 (56%)* 1.8
Chronic 
hepatitis C
13 2/10 (20%) 0.20 5/20 (25) 0.30 - -
Anti-HCV+/
HCV-RNA-
9 3/9 (33%) 0.44 5/12 (42%) 0.42 - -
* Only 4 pts were HLA-A2 pos
Peptide screen in patient 36 Figure 3
Peptide screen in patient 36. Only subject #36 mounted a 
robust multispecific response against at least 5 peptides after 
clearance of HCV at two independent time points (figure 2). 
Patient #1 tested positive for one HCV-class II peptide at the 
first time-point investigated and was negative for all peptides 
on subsequent time points. Patients #5, #10, #13, #27, and 
#80 tested negative for all peptides at all time-points investi-
gated. All other patients tested negative in this assay.
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HCV-RNA declines, there might be a high chance for
spontaneous clearance even in asymptomatic patients.
(iii) HCV-specific CD4+ T cell responses were rather weak
or even undetectable and all subjects cleared HCV any-
way. Clearance of HCV has been associated with strong
and multispecific cellular immune responses in chimpan-
zees and humans [2]. Our findings are not completely in
line with this dogma but are supported by at least one
report on chimpanzees where also no correlation of HCV-
specific adaptive immunity with HCV clearance was evi-
dent [14]. In our study, HCV-specific CD4+ responses
were completely undetectable in 2 subjects and rather
weak in the remaining 5 individuals despite clearance of
HCV. These responses did not differ in strength and spe-
cificity from chronically infected control subjects. Of note,
identical methods were applied and even the same pro-
teins were used for the in vitro stimulation of T cells in the
different assays as in our own previous studies [23-
25,34,35] and also as in studies from other laboraties.
Moreover, the low frequency and strength of T cells in our
assays could not be explained by a mismatch of HCV pro-
teins used for stimulation in the in vitro assays with the
HCV genotype infecting the patients since all subjects had
been infected with HCV genotype 1. In contrast, HCV-spe-
cific CD8+ T cell cells were found by tetramer staining in
three of the four patients, although the frequencies of
tetramer-positive cells were rather low in 2 of them as they
did not exceed 0.2% of CD8+ T cells which was much
lower as compared to our own experience on sympto-
matic acute hepatitis C patients [25] and also as compared
to other reports on human subjects who cleared HCV
spontaneously [8-10,12]. Nevertheless, the finding that
three out of four HLA-A2 positive patients displayed HCV-
specific CD8+ suggests that indeed T cell responses have
been primed and that CD8+ T cells may have contributed
to clearance of HCV. Importantly, the overall low fre-
quency of HCV-specific T cells in the subjects investigated
here was confirmed by T cell testing in a second, inde-
pendent laboratory using a GCP-validated ELISPOT assay
used for investigation of PBMC in clinical trials [28].
What could be the reasons for the lack of an apparent
association between HCV-specific CD4+ T cell responses
and recovery from HCV? First, our data suggest that low
levels of HCV viremia as found in our seven cases may be
controlled by innate immune responses without a strong
adaptive immunity. Data derived from chimpanzees
indeed have demonstrated that early intrahepatic induc-
tion of interferon-response genes without significant
recruitment of HCV-specific T cells leads to significant
reduction of HCV viral load [5]. Moreover, also Post et al.
described a rather low strength of T cell responses in their
two subjects with HCV clearance in the absence of sero-
conversion [15]. However, since we had not enough
PBMC available to apply an overlapping peptide
approach in our patients we might have missed some
CD4+ and very likely some CD8+ T cell responses
although the second screening with a panel of 30 peptides
covering >85% of HLA types should have picked most
responses. Nevertheless, the overall strength of responses
might have been underestimated in our study. However,
the important message is that the strength and frequency
of T cell responses in patients with spontaneous clearance
was not different from chronically infected or long-term
recovered patients.
Also for HIV infection it has been shown that an antigenic
threshold for maintaining cytotoxic T cell responses may
be required [36]. The required levels of antigenic stimula-
tion may not have been reached in our patients but innate
immune responses may have led suppression of HCV rep-
lication. We also do not know, if our patients had been
exposed to HCV before. Four of the seven patients were IV
drug addicts with a duration of abuse of 18–72 months
before incarceration. Higher rates of HCV clearance in iv-
drug addicts have been reported. However, previous con-
tact to HCV and re-exposure should have led to an expan-
sion of adaptive immune responses which were not
detectable in our patients. The lower HCV-RNA levels in
our patients may be also explained by the route of expo-
sure since three out of four subjects who did not develop
anti-HCV antibodies had reported sexual exposure while
almost all chronically infected patients were IV drug
addicts.
For five of the seven patients we do not know how long
these individuals had been viremic prior to imprisonment
and thus we may have missed peak HCV-RNA levels and
also some adaptive immune responses occurring prior to
imprisonment. However, the main message of this manu-
script is that HCV was cleared in patients without the
development of anti-HCV antibodies in 4 out of 7 individ-
uals. Moreover, CD4+ T cell responses are usually main-
tained for some time after clearance if no spontaneous
relapse occurs as shown already in 1999 by Gerlach et al.
[37].
Homing of T cells to the liver has been described in chim-
panzees during acute HCV infection [5]. It is not possible
to perform liver biopsies in patients with acute hepatitis C
since there is no clinical indication for this invasive proce-
dure. Thus, we can not exclude the presence of stronger
intrahepatic HCV-specific T cells in our patients.
One could question if subjects #1, #13 and #36 indeed
had acute hepatitis C since HCV-RNA tested positive only
once in the absence of anti-HCV and thus the HCV-PCR
could have been false-positive. However, a positive HCV-
PCR result was always double checked and investigated byVirology Journal 2007, 4:58 http://www.virologyj.com/content/4/1/58
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both qualitative and quantitative PCR. Moreover, Patient
#36 mounted a significant and broad HCV-specific cellu-
lar immune response (figure 1A and 2) supporting contact
to the hepatitis C virus. Patient #13 had a significant peak
viremia of 7.000 copies/ml making a false positive PCR
result due to contamination rather unlikely and this
patient also showed HCV-specific CD8+ T cells by
tetramer staining.
In conclusion, clearance of HCV-RNA may not necessarily
correlate with the appearance of acquired immunity. This
finding challenges our current understanding of the
immunopathogenesis of HCV-infection and maybe an
explanation for the rather low seroconversion rate after
occupational exposure to HCV. The data should also be
considered in the management of accidental findings of
low levels HCV viremia in asymptomatic individuals
which may have a higher chance of spontaneous clearance
than previously thought.
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